The Wearable Reckoning: MedTech Slept Through a Revolution

  • Wearables are no longer lifestyle accessories. They are becoming core infrastructure for modern healthcare
  • Traditional MedTech was too slow to see that continuous data, not just devices, would create the next strategic battleground
  • The boundary between consumer health and clinical utility is dissolving fast, with major consequences for incumbents
  • Future advantage will come from platforms that support entire therapeutic journeys, not products built for isolated interventions
  • This Commentary explores why MedTech drifted, why wearables matter now, and what traditional players must do

The Wearable Reckoning: MedTech Slept Through a Revolution

Wearables were dismissed as gadgets. That was the strategic mistake. For too long, much of traditional MedTech treated wearables as if they were toys for the anxious well. Interesting, perhaps. Fashionable, certainly. But not serious. Not clinical. Not “real” medicine. That judgement is now colliding with reality.

What many incumbents failed to understand is that wearables were never just about counting steps, logging sleep or nudging consumers to stand up more often. They were the first mass-market infrastructure for continuous physiological observation. While traditional MedTech remained focused on devices designed for single interventions, single departments and single moments of contact, the wearable market evolved into something much more consequential: a persistent, data-generating interface between the human body and the healthcare system.

Wearables are no longer a side market orbiting the edge of medicine. They are becoming one of the foundational layers through which modern healthcare will monitor, interpret and manage patients over time. The global wearable medical devices market is growing rapidly, with multiple analysts placing it on a trajectory >$100B by the end of the decade, driven by ageing populations, chronic disease burdens, remote monitoring, and the wider digitisation of care. Estimates vary, but the direction is unmistakable: this is no side market. It is becoming one of the organising layers of healthcare delivery. 

And yet, with a few exceptions such as Masimo, known for developing patient monitoring devices and software platforms used in hospitals and home settings, traditional MedTechs were slow to act. Many incumbants continued to manufacture and market devices for narrow interventions, while underestimating the strategic significance of longitudinal data, patient-facing platforms, and continuous monitoring. They did not collapse. But they drifted and lost value. The significance of that drift is underlined by Danaher’s February 2026 agreement to acquire Masimo for $9.9 billion: one of the few established MedTech companies to invest meaningfully in platform infrastructure and continuous data has proved valuable not despite that strategic shift, but in part because of it.

The lesson is uncomfortable. The wearable market did not grow because incumbents were wiped out. It grew because incumbents largely kept behaving as if the old categories still held. They assumed the market for wearables was mainly personal, not medical. They assumed consumer technology was adjacent to healthcare rather than increasingly entangled with it. They assumed that because wearables did not match invasive gold standards, they were clinically peripheral. All three assumptions now look increasingly untenable.

The line between personal and medical utility is dissolving. That should alarm traditional MedTech, but it should also clarify what comes next.
 
In this Commentary

This Commentary argues that MedTech underestimated the significance of the wearable revolution, allowing consumer technology companies to reshape how health data are generated, interpreted, and used. It examines why incumbents were slow to respond, what this shift means for clinical practice and industry strategy, and why the consequences now extend far beyond the wrist.
 
The Category Error at the Heart of MedTech’s Delay

Traditional MedTech did not just underestimate a device trend. It misunderstood what the wearable market was producing. A significant share of the sector’s leadership was formed in an era where value resided primarily in the physical device: its engineering, reliability, regulatory approval, installed base and integration into specialist workflows. In that worldview, the medical device was the centre of gravity. Software was an accessory. Data was an output. The clinical encounter was the moment that mattered.

Wearables challenged all of that.

Their significance was never only that they could sit on the wrist, chest or finger. Their significance was that they could sit in time. Traditional devices often generate clinically important snapshots. Wearables generate streams. They capture physiology continuously, or at least repeatedly enough to reveal patterns that snapshots cannot. That difference is not cosmetic. It changes the nature of what can be known, when it can be known, and what can be done with that knowledge. Continuous and longitudinal monitoring enables earlier detection of deterioration, richer context for symptoms, better understanding of recovery, and a more realistic account of how physiology behaves in everyday life rather than only in controlled settings.

This is the strategic point many incumbents missed. The opportunity was not simply to sell a new class of sensor. It was to build a layer of persistent clinical visibility. Once viewed that way, the mistake becomes obvious. Traditional MedTech remained largely organised around interventions. Wearables were building toward journeys.

Breakthrough to Breakdown
- HealthPadTalks' new episode -

Healthcare doesn’t lack innovation—it lacks execution. Breakthroughs don’t fail in labs; they stall in systems built for stability, not speed. Real value comes from implementation across workflows, procurement, and regulation. The winners won’t be those who build more tech, but those who make it work. 
From Episodic Medicine to Continuous Medicine

The classic MedTech model is built around episodic contact. A patient appears at a site of care. A device is used. A measurement is taken. An intervention happens. Data are captured within a bounded event. Reimbursement, workflow and commercial logic all follow that structure.

But many of the most important health problems do not behave episodically. Heart failure worsens between visits. Arrhythmias appear intermittently. Respiratory decline may start subtly. Recovery after surgery unfolds unevenly. Cancer treatment produces changes in fatigue, activity, temperature and physiology that do not neatly coincide with appointments. And as populations in advanced, wealthy economies age, the disease burden itself is changing; chronic lifetime conditions and multi-morbidity are becoming more prevalent, while healthcare systems were largely built for a different disease profile and patient cohort. Chronic disease is lived continuously, even if healthcare has historically observed it intermittently.

Wearables matter because they are one of the first scalable infrastructures capable of narrowing that observational gap. They provide the possibility of following patients across time, across setting and, increasingly, across the full therapeutic journey. In practical terms, that means moving from isolated readings to contextualised trends; from reactive discovery to earlier warning; from hospital-only visibility to distributed monitoring.

That is why today’s wearables are increasingly expected to do far more than track heart rate. The market has moved toward continuous ECG, respiratory metrics, heart rate variability, temperature, oxygen saturation, sleep, posture and activity context, while continuous glucose monitoring has become especially important for many people living with diabetes. In some cases, devices also offer inferred measures such as blood pressure, stress, hydration status, or recovery. The important shift is not simply the growing number of metrics. It is the emergence of wearables as multi-physiologic platforms: sensing systems rather than single-purpose trackers.

For MedTech incumbents, this should be a strategic shock. The company that owns the most valuable part of the patient journey may no longer be the company with the strongest device at a single intervention point. It may be the company that can monitor, interpret and support the patient most effectively across time.
 
The Consumer-Health Boundary is Breaking Down

Perhaps the most damaging assumption inside traditional MedTech was the idea that the wearable market belonged to lifestyle rather than medicine. That distinction once appeared neat. Consumer devices were for fitness, wellness and self-optimisation. Medical devices were for diagnosis, treatment and clinical care. But that boundary has been eroding for years, and now it is dissolving fast.

Apple is the obvious case, even if earlier consumer wearables such as Fitbit helped familiarise users with the idea of continuous personal health tracking. The Apple Watch did not begin by trying to resemble a traditional medical device. It entered through habit, design, convenience and ecosystem integration. Yet over time it gained FDA-cleared ECG capabilities and established itself as a serious participant in arrhythmia screening and atrial fibrillation awareness. Its importance is not that it replaced cardiology. It is that it normalised the idea that clinically relevant health monitoring could exist in an everyday consumer device worn by millions.

That changes expectations everywhere else.

Patients begin to wonder why their smartwatch can surface trends their formal care pathway ignores. Clinicians begin to ask which parts of consumer-generated data may be useful for triage, follow-up or escalation. Health systems begin to explore whether lower-cost continuous monitoring can reduce unnecessary admissions or detect deterioration earlier. Payers begin to look for evidence that remote monitoring can lower downstream costs.
You might also like:
 
The key point is not that every consumer wearable is clinically robust. Many are not. The point is that the market has changed the cultural expectation of what monitoring can be. Once the public becomes accustomed to passive, continuous, always-on physiological insight, the old model of healthcare waiting for the patient to arrive before observing them starts to look increasingly archaic.
Traditional MedTech underestimated this because it focused too heavily on what wearables were not. They were not invasive. They were not always gold-standard. They were not confined to clinical settings. They were not sold through the familiar institutional channels. But that scepticism obscured what they were becoming: the everyday interface through which health data enters routine life.
 
Accuracy is Not the Whole Argument. Clinical Relevance Is

One reason incumbents were able to dismiss wearables for so long is that many wearable measurements did not match the precision of invasive or hospital-grade reference systems. This criticism was never entirely wrong. Signal quality matters. Motion artefact matters. Validation matters. Gold standards exist for good reasons.

But the criticism was strategically incomplete.

Wearables do not need to replace invasive devices to be transformative. They need to produce signals that are clinically relevant enough to change decisions, allocate attention more intelligently or flag deterioration early enough to matter. For many use cases, the comparator is not the best possible measurement under ideal conditions. It is the absence of continuous information.

That distinction matters. A wearable ECG does not have to replace a full cardiology work-up to be valuable. A respiratory trend monitor does not have to replace spirometry to signal that a patient is worsening. A multi-parameter patch does not need to achieve the perfection of ICU monitoring to reduce blind spots in recovery or step-down care. In many settings, an early directional signal with appropriate workflow integration can be more valuable than a pristine reading that arrives too late.

This is where the phrase “actionable trends” becomes more important than “raw accuracy”. The frontier for health wearables is not whether they produce elegant streams of data for their own sake. It is whether they can meaningfully signal risk before a crisis, inform escalation, support monitoring and improve allocation of clinical attention.

Traditional MedTech should understand this better than most. Yet too often it has remained trapped in an all-or-nothing mindset: either a device is diagnostic-grade, or it is strategically secondary. That is the wrong frame for a healthcare environment increasingly defined by prevention, surveillance, stratification and remote care.

MedTech Built Products. Wearables are Building Platforms.

This is the deeper challenge. Traditional MedTech companies are typically organised around products, categories and sales channels: a cardiac product line sits here, a respiratory line sits there, a monitoring business sells into one part of the hospital, and a surgical business into another. Success is measured through familiar commercial metrics such as unit sales, account penetration, consumables and service contracts - indicators that feed neatly into quarterly reporting, revenue visibility and earnings calls, and which, over time, have come to shape much of the executive mindset in the sector.

Wearables destabilise that logic because their value does not end at the sensor. It begins there.

The strategic asset is the platform that sits above the sensor: the data architecture, the analytics layer, the workflow integration, the alerting logic, the patient interface, the clinician dashboard, the interpretation models, the interoperability with broader health IT systems. In other words, the device is still important, but it is no longer sufficient.

This is where traditional MedTech’s legacy strengths can become constraints. Their commercial models are often transactional. Their organisational structures are often departmental. Their software capabilities may be fragmented. Their digital investments may still be treated as support functions rather than core strategy. They know how to sell a device. They are less practiced at managing an ongoing data relationship with patients across months or years.

The wearable era rewards different kinds of strength. It rewards firms that can accumulate longitudinal datasets, translate physiological streams into useful risk signals, integrate monitoring into care workflows, and maintain engagement outside the clinic. It rewards interoperability rather than siloed device logic. It rewards persistence rather than event-based contact.

The winners will look less like catalogue companies and more like platform companies. That does not mean every MedTech firm must become Apple. However, it does mean they must stop pretending that hardware alone will remain the centre of defensibility.
 
Why Consumer Technology Learned Faster

There is also a cultural lesson in all this. Consumer technology companies often moved faster not because they understood medicine better, but because they understood adoption better.

Healthcare has long excelled at seriousness, engineering and clinical validation. Consumer technology excels at usability, behaviour and habit formation. In a world of continuous monitoring, that difference matters. The best wearable in the world is useless if patients do not wear it, charge it, trust it or understand it. Longitudinal value depends not only on signal quality, but on sustained human use.

This is where many incumbents were weakest. They judged performance mainly in technical terms, not behavioural ones. Yet what matters in the real world is not simply whether a device performs well in principle, but whether patients will use it consistently. A device that is slightly less sophisticated but fits easily into everyday life can therefore be more valuable than a technically superior one that patients stop using.

This is another reason the “lifestyle” dismissal is strategically foolish. Consumer markets solved adherence, comfort, interface and routine interaction earlier than MedTech did. And those capabilities are not superficial. They are central to the success of remote and continuous monitoring.

The phrase “digital immigrants” may sound harsh, but it captures something real about leadership mindset. Many executives trained in a pre-platform era interpret digital as a wrapper around the product: an app, a dashboard, a software add-on. But in platform markets, digital is not the wrapper. It is the business logic. Wearables exposed that difference.
 
The Therapeutic Journey is now the Real Battleground

The most important strategic lesson for traditional MedTech is that healthcare value is shifting from isolated interventions toward the orchestration of whole patient journeys.
A heart failure patient does not care that one company owns a monitor, another owns a diagnostic device and a third owns a post-discharge patch. They experience a single journey: symptoms, observation, deterioration risk, hospital contact, discharge, recovery, relapse prevention. Likewise, an oncology patient, a respiratory patient or a post-operative patient does not live inside neat device categories. They live inside uncertain therapeutic trajectories.
You might also like to listen to:
 
The company that matters most in that environment is not necessarily the one with the single most impressive piece of hardware. It is the one that can generate meaningful visibility across the journey and turn that visibility into support, interpretation and action.

This is why journey-centric design should replace intervention-centric design as MedTech’s organising principle.

For each therapeutic area, incumbents should be asking harder questions. Where are the blind spots between visits? Which signals change before symptoms become severe? Which data can be collected passively rather than requiring effort from the patient? Which alerts are clinically actionable rather than just noisy? How should information move between patient, clinician, caregiver and system? Which parts of the pathway demand medical-grade certainty, and which are well served by reliable early-warning systems?

These are not just product questions. They are strategic questions about where value is created.
 
Traditional MedTech Still Has Advantages. But only if it Changes the Frame

This is not a story in which incumbent MedTech is doomed and consumer technology wins by default. Traditional MedTech still possesses formidable assets: regulatory experience, clinical credibility, provider relationships, knowledge of pathways and the ability to operate in high-stakes settings where trust matters.

But those strengths only matter if they are reassembled around the realities of continuous, connected care.

A useful example comes from enterprise and hospital monitoring, where firms such as Philips are beginning to frame wearables not as standalone gadgets but as interoperable elements within wider patient-monitoring architectures. Philips, for instance, describes an “end-to-end” monitoring solution built around live device data and, in its smartQare partnership, explicitly positions wearable sensing as part of continuous monitoring “in and out of the hospital,” linking observation across bedside, ward and home settings. That is much closer to the right strategic frame. The product is no longer the device in isolation, but the monitored patient journey it helps make visible.

This is where incumbents can still win. They can build clinically robust wearables for high-value pathways such as cardiac monitoring, respiratory deterioration, post-operative recovery, oncology support or chronic disease management. They can become workflow integrators, using third-party sensors where necessary but owning the orchestration layer. They can focus on analytics, translating streams of noisy physiology into useful risk models and escalation pathways. They can build trusted bridges between consumer-generated data and formal clinical systems.

But they will not win by bolting generic software onto legacy hardware and calling it transformation.
 
The Risks are Real. Denial is Worse

None of this means the wearable future is frictionless. Signal quality remains uneven. Many devices are over-marketed and under-validated. False positives can create anxiety. False negatives can create false reassurance. Remote monitoring can swamp clinicians with noise if not carefully designed. Interoperability remains poor. Reimbursement is still inconsistent across markets. Data privacy and governance are concerns. Health systems are not yet built to metabolise continuous data gracefully.

But these are not arguments for treating wearables as marginal. They are arguments for building better systems around them. Healthcare has always advanced through the combination of new capability and institutional adaptation. The strategic failure would be to wait for the market to become perfect before taking it seriously.

In fact, incumbents should recognise that these frictions are where their capabilities ought to matter most. Clinical governance, validation, regulatory navigation and pathway design are not side issues. They are how wearables move from promising consumer technologies to trusted components of care.

The mistake is not caution but mistaking caution for strategy.
 
The Real Danger is Strategic Drift, Not Collapse

The most important warning for traditional MedTech is that disruption in healthcare rarely looks dramatic at first. Incumbents often do not fail overnight. They continue generating revenue, servicing installed bases and selling into established channels. The balance sheet looks stable. The products still work. The clinician relationships remain intact. Nothing appears to be collapsing.

But underneath, value migrates.

It migrates into data assets, patient interfaces, workflow platforms, predictive models and continuous relationships. It migrates toward firms that understand how to live with the patient beyond the clinical encounter. It migrates toward systems that make deterioration visible earlier, care more distributed and intervention more targeted.

That is the kind of strategic drift the wearable market has exposed. Traditional MedTech did not implode. It simply underestimated where the future centre of gravity was moving. That is often how industries lose their strategic position: not through spectacular failure, but through outdated categories.
 
Takeaways

The wearable market is not just another adjacent segment for MedTech to notice late and enter cautiously. It is a warning about the future structure of healthcare technology. The next generation of winners will not think of themselves only as device manufacturers. They will think of themselves as managers of physiological intelligence across the therapeutic journey. They will combine sensing, software, analytics, patient engagement, workflow integration and services. They will understand the difference between diagnostic perfection and decision-grade usefulness. They will know when clinical-grade precision is necessary and when timely directional insight is what changes outcomes. Most importantly, they will stop treating data as a by-product of the device and start treating it as the basis of the business.

That is the sharper strategic lesson for traditional MedTech. The future will not be won solely in the procedure room, the procurement contract or the single device category. It will also be won on the wrist, on the chest, in the home, across the patient pathway and within the data streams that reveal risk before crisis.

Wearables began at the margins of medicine because incumbents were too comfortable calling them lifestyle devices. They are moving toward the centre because healthcare increasingly needs what they provide: continuity, context, earlier warning and a more patient-centred model of observation.

Traditional MedTech can still respond. But it must do so by abandoning one of its most persistent illusions: that the serious business of medicine begins only when the patient reaches the clinic. Increasingly, it begins long before that. And the companies that understand this will not just build better devices. They will redefine what a medical technology company is.

Comments

comments